Business
TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its Phase I clinical trial has received their initial dose. TransCode also reported that two additional patients in Cohort 4 are scheduled to receive TTX-MC138. The therapeutic candidate being evaluated, TTX-MC138, is TransCode's lead candidate designed to inhibit microRNA-10b, a microRNA critical to the
About this update from Transcode Therapeutics, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"First patient in Cohort four has been treated with TTX-MC138","length":60,"tagName":"p"}]},{"val":[{"type":"text","content":"Ten patients have been treated with TTX-MC138 at escalating dose levels","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"Additional patients being evaluated for eligibility for expanded enrollment","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"No significant safety or dose limiting toxicities have been reported","length":68,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":274,"olType":false},{"type":"text","content":"BOSTON, March 27, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its Phase I clinical trial has received their initial dose. TransCode also reported that two additional patients in Cohort 4 are scheduled to receive TTX-MC138. The therapeutic candidate being evaluated, TTX-MC138, is TransCode's lead candidate designed to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metastatic cancer. No significant safety or dose limiting toxicities have been reported. The dose administered to the fourth cohort, as originally planned in the clinical protocol, is approximately fifty percent higher than the dose administered in the third cohort.","length":866,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/TransCode Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/TransCode Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":58,"url":"https://media.zenfs.com/en/prnewswire.com/6158e3f623b2cdcf70a213bfe6b5eb12"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y2kxVj5Zztrmutz6upX.Ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/6158e3f623b2cdcf70a213bfe6b5eb12","width":400,"height":58}},"href":"https://mma.prnewswire.com/media/2583692/TransCode_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under the clinical protocol, patients may remain on study absent safety events or disease progression. Of the ten patients treated with TTX-MC138 in the fi...